China Stock Market Research & China Stock Analysis
- Profits of 30%, 50% & More
- Rated #1 China Stock Market Newsletter by Dow Jones
- Largest Equity Research Firm Covering all 4 China Stock Markets
- Expert on China Stock Market Investing
- Featured On Fox Business News as China Stock Market Expert
Jim
Trippon Is America's Foremost Expert On China Stock
Market Investing
China Shenghuo Pharmaceutical Holdings - KUN - blends traditional
Chinese medicine with modern pharmacology to treat the ills
of the East. The company makes a variety of pharmaceutical,
nutritional, and cosmetic products using Panax notoginseng as
its primary ingredient. Xuesaitong Soft Capsules account for
most of company sales and are used in the treatment of cardiovascular
and cerebrovascular disease. Other prescription products treat
headaches, cold and flu symptoms, and rheumatoid arthritis,
while its over-the-counter products include supplements, vitamins,
and health-promoting preparations. China Shenghuo Pharmaceutical
sells substantially all of its products in China.
China Shenghuo Pharmaceutical Holdings - KUN state-of-the-art
factories in the Kunming National Economy & Technology Developing
District in mainland China have a combined production capacity
of 1.5 billion soft capsules per year.China Shenghuo Pharmaceutical
Holdings - KUN advanced manufacturing procedures and effective
quality control enable it to provide pharmaceutical products
according to more stringent Western standards.
Founded
in 1995, China Shenghuo Pharmaceutical Holdings - KUN is a leading
specialty pharmaceutical company that focuses on the research,
development, production and marketing of Sanchi-based medicinal
products. China Shenghuo Pharmaceutical Holdings - KU
owns
thirty-one SFDA (State Food and Drug Association)-approved medicines,
including the flagship product Xuesaitong Soft Capsules, which
has already been listed in the Insurance Catalogue. China Shenghuo
Pharmaceutical Holdings - KUN incorporates
a sales network of agencies and representatives throughout China,
which markets Sanchi-based traditional Chinese medicine into
1,650 hospitals and 1,500 drug stores as prescription and OTC
drugs primarily for the treatment of cardiovascular, cerebrovascular
and peptic ulcer disease. China Shenghuo Pharmaceutical Holdings
- KUN also
exports medicinal products to Asian countries such as Indonesia,
Thailand and Kyrgyzstan.
Are you earning 30%, 50% or more on your investments? If not, You need China Stock Digest.
